Skip to main
CDNA
CDNA logo

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc has demonstrated robust financial performance with a 19% year-over-year revenue growth in 2024, bolstered by steady quarter-over-quarter increases in testing volume, which reached 45,500 in Q4, marking a 14% increase from the previous quarter. The company's effective growth strategies, including initiatives to enhance testing solutions for transplant centers and expand payer coverage, position it well for an anticipated 17% revenue growth in 2025, with a long-term target of achieving $500 million in revenue by 2027 alongside a 20% adjusted EBITDA. Additionally, CareDx's estimated market value has risen to $1.43 billion, reflecting positive market sentiment and potential for continued financial advancement.

Bears say

CareDx Inc faces several fundamental challenges that contribute to a negative outlook for its stock. The company's financial performance is at risk due to potential reimbursement issues for its testing services, particularly if rates are reduced or if CareDx fails to secure reimbursement altogether. Additionally, increasing competition in the diagnostics sector, along with the potential for tighter healthcare regulations and difficulties in integrating acquisitions, could further hinder the company's market position and financial results.

CareDx (CDNA) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 11 analysts, CareDx (CDNA) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.